ASX Announcement, Chimeric Therapeutics to Undertake Entitlement Offer
Chimeric announces a $3.2M Entitlement Offer to fund CHM CDH17 trials, advancing cell therapy for cancer treatment.
Chimeric announces a $3.2M Entitlement Offer to fund CHM CDH17 trials, advancing cell therapy for cancer treatment.